脂代谢紊乱与CRP水平变化对T2DM合并CHD患者的影响

Influence of lipid metabolic disorder and CRP level on patients with T2DM and CHD

目的观察脂代谢紊乱与CRP水平变化对2型糖尿病(T2DM)合并冠心病(CHD)患者的影响。方法 98例健康体检者为对照组(A组),85例经临床确诊T2DM患者为B组,以及55例经临床确诊T2DM合并CHD患者为C组,采用全自动生化分析仪检测血清甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、血清载脂蛋白A1(ApoA1)、载脂蛋白B(ApoB)、ApoA1/ApoB、HDL-C/LDL-C、HDL-C/TC浓度;采用免疫比浊法测定血清CRP水平。结果与A组比较,B组、C组TG、TC、LDL-C、ApoB、CRP水平明显升高,HDL-C、ApoA1、ApoA1/ApoB、HDL-C/LDL-C、HDL-C/TC浓度明显降低;与B组比较,C组患者TG、TC、LDL-C、ApoB、CRP水平明显升高。结论 T2DM合并CHD患者与单纯T2DM患者脂质代谢发生紊乱,血清TG、TC、LDL-C、ApoB、CRP水平明显升高,HDL-C、ApoA1、ApoA1/ApoB、HDL-C/LDL-C、HDL-C/TC浓度明显降低;早期诊断及时治疗与预后密切相关,诊治过程中应控制脂代谢紊乱与CRP水平变化,有助于提高治疗效果,改善预后,防止或延缓并发症发生。

Objective To observe the influence of lipid metabolic disorder and CRP level change on patients with T2DM and CHD. Methods Ninety - eight healthy people acted as control group（ A）, 85 clinically diagnosed patients with T2DM served as observation group （B）, 55 clinically diagnosed patients with T2DM and CHD served as observation group （C）. The concen- trations of serum triglycerides （TG）, total cholesterol （TC）, low density lipoprotein, cholesterol （LDL- C）, high density lipo- protein cholesterol （HDL- C）, serum apolipoprotein A1 （ApoA1）, apolipoprotein B （ApoB）, ApoA1/ApoB, HDL- C/LDL - C, and HDL - C/TC were determined with automatic biochemical analyzer, while the serum CRP levels were measured by im- munoturbidimetry. Results Compare to the control, group A, the levels of TG, TC, LDL - C, ApoB and CRP in observation groups （ B, C） were significantly higher, while those of HDL - C, ApoA1, ApoA1/ApoB, HDL - C/LDL - C, HDL - C/TC were significantly lower, the differences all bad statistical significance. The levels of TG, TC, LDL - C, ApoB and CRP in C group were obviously higher than those in B group. Conclusion Obvious increase of TG, TC, LDL - C, ApoB and CRP levels and significant decrease of HDL - C, ApoA1, ApoA1/ApoB, HDL - C/LDL - C, HDL - C/TC are found in simple T2DM patients and the patients with T2DM and CHD. Early diagnosis and timely treatment have close relationship with prognosis, the lipid me- tabolism disorder and CRP levels during the diagnosis and treatment process should be controlled to improve the therapeutic effect and prognosis, prevent or delay cardiovascular disease and other complications.